Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
Computerized cognitive training interventions may offer a small benefit for overall cognitive outcomes in adults with attention-deficit/hyperactivity disorder (ADHD), according to a systematic review and meta-analysis published in...
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
A beta version of a prescription digital therapeutic significantly reduced experiential negative symptoms in patients with schizophrenia, according to a poster presentation at Psych Congress.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
An online pain management program reduced anxiety and depressive symptoms in adults with chronic pain, according to study results published online ahead of print in Pain Medicine.
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
The US Food and Drug Administration has provided Magnus Medical Inc. 510(k) clearance for the SAINT Neuromodulation System for the treatment of MDD in adults who have not achieved adequate improvement from prior antidepressant medications in...
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
Four weeks of daily, home-based transcranial direct current stimulation (tDCS) improved attention in adults with ADHD not taking stimulant medication, according to a small sham-controlled trial.
The FDA recently granted Abbott a breakthrough device designation to investigate the use of its deep brain stimulation system for patients with treatment-resistant depression, a form of major depressive disorder.
The FDA recently granted Abbott a breakthrough device designation to investigate the use of its deep brain stimulation system for patients with treatment-resistant depression, a form of major depressive disorder.
Vortioxetine was consistently associated with reduced depressive symptoms in older adults with MDD, while its effects on cognition were less consistent, according to a systematic review.
Vortioxetine was consistently associated with reduced depressive symptoms in older adults with MDD, while its effects on cognition were less consistent, according to a systematic review.
Semaglutide initiation was associated with fewer clinician-recorded cognitive signs and symptoms among adults with psychiatric disorders, according to a poster presented at Psych Congress.
Semaglutide initiation was associated with fewer clinician-recorded cognitive signs and symptoms among adults with psychiatric disorders, according to a poster presented at Psych Congress.
Negative expectations about the future were associated with differences in brain structure and a longer course of depressive illness among patients with MDD.
Negative expectations about the future were associated with differences in brain structure and a longer course of depressive illness among patients with MDD.
Participants in Oregon’s state-regulated psilocybin program reported improvements in depression, anxiety, PTSD symptoms, mental well-being, and life satisfaction over 3 months.
Participants in Oregon’s state-regulated psilocybin program reported improvements in depression, anxiety, PTSD symptoms, mental well-being, and life satisfaction over 3 months.
Treating MDD during pregnancy should be prioritized as part of maternal and fetal health care, argued the authors of a Special Communication published in JAMA Psychiatry.
Treating MDD during pregnancy should be prioritized as part of maternal and fetal health care, argued the authors of a Special Communication published in JAMA Psychiatry.
In a preregistered study of 106 adults, individuals with major depressive disorder (MDD) reported more mind-wandering than healthy controls during a continuous performance task.
In a preregistered study of 106 adults, individuals with major depressive disorder (MDD) reported more mind-wandering than healthy controls during a continuous performance task.
Baseline alcohol, nicotine, and cannabis use was largely not associated with antidepressant response to rTMS among patients with MDD, according to study findings.
Baseline alcohol, nicotine, and cannabis use was largely not associated with antidepressant response to rTMS among patients with MDD, according to study findings.
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Patients with TRD receiving repeated, low-dose oral esketamine did not experience greater increases in serum BDNF than those receiving placebo, according to study findings.
Patients with TRD receiving repeated, low-dose oral esketamine did not experience greater increases in serum BDNF than those receiving placebo, according to study findings.
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Steven Chan, MD, MBA, discusses the expectations clinicians should set when utilizing apps in their clinical practice and how to integrate them with electronic health record (EHR) systems.
Michael Asbach, DMSc, PA-C, Clinical Editor, Psych Congress Journal, explores key concepts from his Psych Congress 2026 session, “Could Glutamatergic Modulation be the Keystone of Durable Change in Treatment-Resistant Depression?”
Michael Asbach, DMSc, PA-C, Clinical Editor, Psych Congress Journal, explores key concepts from his Psych Congress 2026 session, “Could Glutamatergic Modulation be the Keystone of Durable Change in Treatment-Resistant Depression?”
The Dr Vladimir Maletic Memorial Scholarship was established to honor the life, legacy, and lasting influence of Dr Vladimir Maletic, a beloved member of the Psych Congress community and exceptional clinician and educator.
The Dr Vladimir Maletic Memorial Scholarship was established to honor the life, legacy, and lasting influence of Dr Vladimir Maletic, a beloved member of the Psych Congress community and exceptional clinician and educator.
Julie Carbray PhD, PMHNP-BC, PMHCNS-BC, FAAN; James Greenblatt, MD
Julie Carbray, PhD, PMHNP-BC, FAAN, and James Greenblatt, MD, discuss how functional impairment, symptom severity, patient preferences, life stage, and family perspectives can shape initial ADHD treatment decisions, as explored at their 2026...
Julie Carbray, PhD, PMHNP-BC, FAAN, and James Greenblatt, MD, discuss how functional impairment, symptom severity, patient preferences, life stage, and family perspectives can shape initial ADHD treatment decisions, as explored at their 2026...
Saundra Jain, MA, PsyD, LPC; Brittany B. Albright, MD, MPH; Brooke Kempf, MSN, PMHNP-BC; Kevin Williams, MS, MPAS, PA-C
In this expert Q&A, leading psychiatry clinicians explore how residual symptoms such as anhedonia, anxiety, and suicidality can inform treatment decisions and why clinicians should look beyond a simple assessment of response.
In this expert Q&A, leading psychiatry clinicians explore how residual symptoms such as anhedonia, anxiety, and suicidality can inform treatment decisions and why clinicians should look beyond a simple assessment of response.
James Greenblatt, MD, discusses where lifestyle, nutritional, and functional medicine strategies may help address gaps in conventional psychiatric care.
James Greenblatt, MD, discusses where lifestyle, nutritional, and functional medicine strategies may help address gaps in conventional psychiatric care.
Craig Chepke, MD, DFAPA; Kevin Williams, MS, MPAS, PA-C
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how clinicians can align major depressive disorder (MDD) treatment goals with patients’ lived experience of anhedonia.
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how clinicians can align major depressive disorder (MDD) treatment goals with patients’ lived experience of anhedonia.
In this conversation with PCN, Arwen Podesta, MD, DFAPA, DFASAM, discusses how medication-assisted therapy (MAT) may improve patient outcomes in alcohol use disorder (AUD).
In this conversation with PCN, Arwen Podesta, MD, DFAPA, DFASAM, discusses how medication-assisted therapy (MAT) may improve patient outcomes in alcohol use disorder (AUD).
Expert Psych Congress faculty discuss how to respond when antidepressant treatment produces improvement without full remission in MDD and why augmentation should be introduced early.
Expert Psych Congress faculty discuss how to respond when antidepressant treatment produces improvement without full remission in MDD and why augmentation should be introduced early.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
